0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

U.S. Dermatological Drugs Market Size, Share & Trends Analysis Report by Therapy (Acne, Psoriasis), Type (Prescription, Over-The-Counter), Route of Administration, Drug Class, Distribution Channel with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 80 Pages
  • February 2025
  • Region: United States
  • Grand View Research
  • ID: 6055969
The U.S. Dermatological Drugs Market was valued at USD 8.32 billion in 2024, and is projected to reach USD 14.48 billion by 2030, rising at a CAGR of 9.70%. The growth of the market is driven by the availability of novel treatments designed for chronic skin diseases and the increasing prevalence of skin problems such as acne, psoriasis, and others. Increasing awareness regarding the significance of skin health in overall well-being also contributes to the growth.

Moreover, significant investments in research and development lead to new medications, and the availability of over-the-counter products makes treatments more accessible, contributing to overall growth. In recent years, multiple pharmaceutical and consumer healthcare companies have received U.S. FDA approvals for innovation-based products developed to treat severe skin conditions and enhance patient outcomes.

The emergence of new drug delivery systems and key market participants turning to collaboration-based research efforts in dermatology have also played vital roles in the market's growth. The large number of individuals seeking affordable treatments, the availability of over-the-counter products across retail pharmacies, and retailer service expansions with novel offerings such as fast delivery and online distribution are projected to add lucrative growth opportunities for this market over the forecast period.

U.S. Dermatological Drugs Market Report Highlights

  • Psoriasis dominated the therapy segment with more than 35.0% share in 2024, owing to many individuals seeking effective treatment for psoriasis and the focus of market participants on the delivery of novel therapies
  • Dermatological drugs for acne are expected to grow at a significant CAGR in the U.S. over the forecast period
  • The prescription-based dermatological drugs held the largest market share, 77.5%, in 2024. The over-the-counter segment is anticipated to witness significant growth over the forecast period
  • Topical administration dominated the U.S. dermatological drugs market, with a revenue share of 60.0% in 2024, owing to patients' treatment experiences, patient-friendly delivery systems, and ease of use. The parenteral administration segment is expected to witness the fastest CAGR of 10.7% over the forecast period
  • Increasing investments in research and development, approvals received for numerous novel therapies and products, and convenience offered by retail pharmacies are contributing to the growth of the U.S. dermatological drugs market.

This report addresses:

  • Market intelligence to enable effective decision-making.
  • Market estimates and forecasts from 2018 to 2030.
  • Growth opportunities and trend analyses.
  • Segment and regional revenue forecasts for market assessment.
  • Competition strategy and market share analysis.
  • Product innovation listings for you to stay ahead of the curve.
  • COVID-19's impact and how to sustain in this fast-evolving market.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Therapy
1.2.2. Type
1.2.3. Route of Administration
1.2.4. Drug Class
1.2.5. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Dermatological Drugs Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. U.S. Dermatological Drugs Market: Therapy Estimates & Trend Analysis
4.1. Therapy Market Share, 2024 & 2030
4.2. Therapy Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
4.4. Acne
4.4.1. Acne Market, 2018-2030 (USD Million)
4.5. Psoriasis
4.5.1. Psoriasis Market, 2018-2030 (USD Million)
4.6. Rosacea
4.6.1. Rosacea Market, 2018-2030 (USD Million)
4.7. Alopecia
4.7.1. Alopecia Market, 2018-2030 (USD Million)
4.8. Others
4.8.1. Others Market, 2018-2030 (USD Million)
Chapter 5. U.S. Dermatological Drugs Market: Type Estimates & Trend Analysis
5.1. Type Market Share, 2024 & 2030
5.2. Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
5.4. Prescription
5.4.1. Prescription Market, 2018-2030 (USD Million)
5.5. Over-the-Counter (OTC)
5.5.1. Over-the-Counter (OTC) Market, 2018-2030 (USD Million)
Chapter 6. U.S. Dermatological Drugs Market: Route of Administration Estimates & Trend Analysis
6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Topical Administration
6.4.1. Topical Administration Market, 2018-2030 (USD Million)
6.5. Oral Administration
6.5.1. Oral Administration Market, 2018-2030 (USD Million)
6.6. Parenteral Administration
6.6.1. Parenteral Administration Market, 2018-2030 (USD Million)
Chapter 7. U.S. Dermatological Drugs Market: Drug Class Estimates & Trend Analysis
7.1. Drug Class Channel Market Share, 2024 & 2030
7.2. Drug Class Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
7.4. Corticosteroids
7.4.1. Corticosteroids Market, 2018-2030 (USD Million)
7.5. Retinoids
7.5.1. Retinoids Market, 2018-2030 (USD Million)
7.6. Antibiotics
7.6.1. Antibiotics Market, 2018-2030 (USD Million)
7.7. Antifungals
7.7.1. Antifungals Market, 2018-2030 (USD Million)
7.8. Calcineurin Inhibitors
7.8.1. Calcineurin Inhibitors Market, 2018-2030 (USD Million)
7.9. Others
7.9.1. Others Market, 2018-2030 (USD Million)
Chapter 8. U.S. Dermatological Drugs Market: Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel Market Share, 2024 & 2030
8.2. Distribution Channel Segment Dashboard
8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
8.4. Hospital Pharmacies
8.4.1. Hospital Facilities Market, 2018-2030 (USD Million)
8.5. Retail Pharmacies
8.5.1. Retail Facilities Market, 2018-2030 (USD Million)
8.6. Ohers
8.6.1. Others Market, 2018-2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. AbbVie Inc.
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Pfizer Inc.
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. GSK plc.
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. LEO Pharma A/S
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Sun Pharmaceutical Industries Ltd.
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. GALDERMA
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Amgen Inc.
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Johnson & Johnson Services Inc.
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Novartis AG
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Eli Lilly and Company
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
9.5.11. Almirall, S.A
9.5.11.1. Overview
9.5.11.2. Financial Performance
9.5.11.3. Product Benchmarking
9.5.11.4. Strategic Initiatives
9.5.12. Bausch Health Companies Inc.
9.5.12.1. Overview
9.5.12.2. Financial Performance
9.5.12.3. Product Benchmarking
9.5.12.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 U.S. dermatological drugs market, by therapy, 2018-2030 (USD Million)
Table 4 U.S. dermatological drugs market, by type, 2018-2030 (USD Million)
Table 5 U.S. dermatological drugs market, by route of adminstration, 2018-2030 (USD Million)
Table 6 U.S. dermatological drugs market, by drug class, 2018-2030 (USD Million)
Table 7 U.S. dermatological drugs market, by distribution channel, 2018-2030 (USD Million)
List of Figures
Figure 1 U.S. dermatological drugs market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Therapy and type outlook (USD Million)
Figure 10 Route of administration & drug class outlook (USD Million)
Figure 11 Distribution channel outlook (USD Million)
Figure 12 Competitive landscape
Figure 13 U.S. dermatological drugs market dynamics
Figure 14 U.S. dermatological drugs market: Porter’s five forces analysis
Figure 15 U.S. dermatological drugs market: PESTLE analysis
Figure 16 U.S. dermatological drugs market: Therapy segment dashboard
Figure 17 U.S. dermatological drugs market: Therapy market share analysis, 2024 & 2030
Figure 18 Acne market, 2018-2030 (USD Million)
Figure 19 Psoriasis market, 2018-2030 (USD Million)
Figure 20 Rosacea market, 2018-2030 (USD Million)
Figure 21 Alopecia market, 2018-2030 (USD Million)
Figure 22 Others market, 2018-2030 (USD Million)
Figure 23 U.S. dermatological drugs market: Type segment dashboard
Figure 24 U.S. dermatological drugs market: Type market share analysis, 2024 & 2030
Figure 25 Prescription market, 2018-2030 (USD Million)
Figure 26 Over-the-Counter (OTC) market, 2018-2030 (USD Million)
Figure 27 U.S. dermatological drugs market: Route of administration segment dashboard
Figure 28 U.S. dermatological drugs market: Route of administration market share analysis, 2024 & 2030
Figure 29 Topical administration market, 2018-2030 (USD Million)
Figure 30 Oral administration market, 2018-2030 (USD Million)
Figure 31 Parenteral administration market, 2018-2030 (USD Million)
Figure 32 U.S. dermatological drugs market: Drug class segment dashboard
Figure 33 U.S. dermatological drugs market: Drug class market share analysis, 2024 & 2030
Figure 34 Corticosteroids market, 2018-2030 (USD Million)
Figure 35 Retinoids market, 2018-2030 (USD Million)
Figure 36 Antibiotics market, 2018-2030 (USD Million)
Figure 37 Antifungals market, 2018-2030 (USD Million)
Figure 38 Calcineurin inhibitors market, 2018-2030 (USD Million)
Figure 39 Others market, 2018-2030 (USD Million)
Figure 40 U.S. dermatological drugs market: Distribution channel segment dashboard
Figure 41 U.S. dermatological drugs market: Distribution channel market share analysis, 2024 & 2030
Figure 42 Hospital pharmacies market, 2018-2030 (USD Million)
Figure 43 Retail pharmacies market, 2018-2030 (USD Million)
Figure 44 Others market, 2018-2030 (USD Million)
Figure 45 Company categorization
Figure 46 Company market position analysis
Figure 47 Strategic framework

Companies Mentioned

The major companies profiled in this U.S. Dermatological Drugs market report include:
  • AbbVie Inc.
  • Pfizer Inc.
  • GSK plc.
  • LEO Pharma A/S
  • Sun Pharmaceutical Industries Ltd.
  • GALDERMA
  • Amgen Inc.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Almirall, S.A
  • Bausch Health Companies Inc.

Methodology

Table Information

This website uses cookies to ensure you get the best experience. Learn more